Filter results by document type and/or working area to find what you're searching for.
This clinical case reports the disease progression of a patient hospitalised due to a SARS-CoV-2 infection. The patient’s condition worsens significantly over time, ultimately leading to the development of an acute respiratory distress syndrome (ARDS), a common but very severe complication in respiratory tract infections (such as COVID-19).
Cerebrospinal fluid as sample material requires particular attention at all times, from sample collection and transport to laboratory diagnostics. Upon arrival at the laboratory, the CSF sample must be processed quickly with great care and expertise so that the analysis results provide the information needed by the physician for treatment decisions. In this article you find a summary of all lab procedures with a focus on cell count and differentiation.
This case report deals with leptomeningeal carcinomatosis, a rare and severe complication of cancer in which the disease spreads into the membranes (meninges) surrounding the brain and spinal cord. In addition to that, it outlines how the HF-BF research parameter can be supportive.
The early differentiation of the underlying cause of canine anaemia is one of the biggest diagnostic challenges for veterinary clinicians. The reticulocyte count, together with the study of the different circulating degrees of maturity may allow a much more thorough and detailed assessment of each patient in the veterinary lab. In this preliminary study, reference ranges have been established for reticulocyte maturity fractions. Following the assessment of more than 150 anaemic patients, the Ecija-Mendoza diagram was created, a diagnostic tool that allows the differentiation between conditions caused by haemolysis, acute haemorrhage and anaemia due to dyserythropoiesis to allow the clinician to quickly form a suspected diagnosis.
Determining the aetiology of thrombocytopenia is of major importance. The immature platelet fraction (IPF) can help you promptly differentiate between ineffective bone marrow production and increased destruction or consumption of platelets. Find out more about the use of this parameter here.
Being diagnosed with haematologic malignancy actually happens either because the patient presents with certain symptoms or – as is becoming increasingly common – there are incidental findings during routine blood screening. This white paper describes how a complete blood count measured on Sysmex XN-Series analysers may reveal significant abnormalities and improve the incidental findings of haematologic malignancies or the relapse of cancer under treatment early on.
Emicizumab (Hemlibra®, Roche Pharma AG) is a humanised, modified, monoclonal immunoglobulin G4 (IgG4) antibody with a bispecific antibody structure. Emicizumab substitutes part of the cofactor function of activated factor VIII (FVIIIa) by bridging activated factor IX (FIXa) and factor X (FX) to restore effective haemostasis in HA individuals.